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OBJECTIVE — The purpose of this pilot study was to evaluate the feasibility of 10-day use of
atranscutaneous,real-time,continuousglucose-monitoring(CGM)system.Allpreviousreports
using different CGM systems were for 3-, 5-, or 7-day use.
RESEARCH DESIGN AND METHODS — On day 1, subjects received the CGM device
(SEVEN System) and underwent training on proper use. Subjects returned to the clinic on days
2,7,and10forin-clinicsessions.Ondays2and7,halfthesubjectsperformedﬁngersticksevery
15minandtheotherhalfhadYellowSpringsInstruments(YSI)samplesdrawnevery15min.On
day 10, all subjects participated in an 8-h in-clinic session with YSI and ﬁngerstick testing.
RESULTS — The median absolute relative difference for CGM versus YSI was 12.6, 11.3, and
14.5% on days 2, 7, and 10, respectively (P  0.63). CGM performed better on day 10 when
compared with self-monitoring of blood glucose as compared with YSI.
CONCLUSIONS — This is the ﬁrst study to document 10-day use of a 7-day CGM system.
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I
mprovement in metabolic control, as
measured by reduction in A1C levels,
has been shown to decrease the inci-
denceandprogressionofbothmicro-and
macrovascular diabetes complications
(1–5). Hypoglycemia is the main limiting
factor in achieving target A1C values for
subjectswithtype1diabetes(6),andself-
monitoringofbloodglucose(SMBG)isan
integral part of intensive diabetes man-
agement(7).Recentavailabilityofcontin-
uous glucose-monitoring (CGM) devices
hasallowedpatientstoviewreal-timeglu-
cose values and glucose trends and re-
ceive alarms/alerts of impending hypo- or
hyperglycemia (8–12).
RESEARCH DESIGN AND
METHODS— The protocol was ap-
proved by the institutional review board,
and 30 adult subjects (20 female) with
type 1 diabetes gave written informed
consent to participate. Mean  SD age
and duration of diabetes were 35.3  7.8
years and 22.3  8.4 years, respectively.
Sixteensubjectswereusingmultipledaily
injections,and14wereoninsulinpumps.
All subjects came to the clinic on day
1 for sensor insertions and training. Sen-
sor replacements were allowed within
72 h of the initial insertion. Two patients
requiredreplacementsensorswithin72h
due to dislodgement of the sensor. In in-
stances where the sensor shut off prema-
turely, subjects were allowed to “restart”
the same initial sensor; one patient had to
restart the sensor within 8 h.
On day 2, all 30 subjects also partic-
ipated in a 6-h in-clinic session. Half the
subjects performed comparative SMBG
ﬁngersticks once every 15 min; the other
half underwent peripheral venous cathe-
terization for Yellow Springs Instruments
(YSI) samples every 15 min. On day 7, 28
patientsreturnedforanother6-hin-clinic
session. The subjects who performed
SMBG ﬁngersticks on day 2 now under-
went peripheral venous catheterization,
and those who previously underwent pe-
ripheral venous catheterization per-
formed SMBG ﬁngersticks. At the end of
the session, subjects stayed for an extra
2 h to restart and calibrate the sensors for
extended use. At home, patients were
asked to do similar ﬁngersticks to assure
accuracy of the sensors. On day 10, 24
patients returned for an 8-h in-clinic ses-
sion,duringwhichallpatientsunderwent
peripheral venous catheterization and
had YSI samples drawn every 15 min.
Two patients had sensors that failed pre-
maturely between 72 and 96 h, and four
other patients could not attend the in-
clinicsessiononday10becauseofsched-
ule conﬂicts and/or bad weather in
Denver, Colorado. All patients also per-
formedSMBGevery15minonday10.At
the end of the session, all sensors were
removed and sensor insertion site assess-
ments were made for any skin irritation/
infections.
The SEVEN sensor unit consists of an
applicator, a sensor probe, and transmit-
ter housing as previously described
(11,12).Afterinitialcalibrationat2h,pa-
tients were instructed to upload at least
one SMBG value every 12 h when glucose
values were stable. Once calibrated, the
receiver displayed glucose values that
wereupdatedat5-minintervals.Thehigh
glucosealertwassetat200mg/dl,andthe
lowglucosealertwassetat80mg/dl.Data
from all receivers were downloaded on
day 10 for analyses.
Statistical analysis methods
Categorical variables such as patient dia-
betes history and baseline characteristics
are summarized using n values and per-
centages. The Kruskal-Wallis nonpara-
metric test was used to compare CGM
system accuracy at different times during
sensorwear.Analyseswereperformedus-
ing SAS software (version 9.1.3; SAS In-
stitute, Cary, NC).
RESULTS— Of the 1,050 paired
points in reference to the YSI measure-
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and 400 mg/dl (range of glucose values
used in this study) and were analyzed
prospectively for various statistics using
sensor glucose values as displayed to sub-
jectsinrealtime.Sensorperformancewas
stable across 10 days of sensor wear (Ta-
ble 1). There is no appreciable difference
intheoverallaccuracyresults;seeTable1
forcorrelationcoefﬁcient,absolutediffer-
ence, and absolute relative difference in-
cluding all the paired data points
(Kruskal-Wallis P  0.05), with minor
changes in the relative difference
(Kruskal-WallisP0.02).Median(inter-
quartile range) of absolute difference to
YSI measurement was 11.8  20.9 mg/dl
(70mg/dl)inthehypoglycemic,13.5
19.5 (70–180 mg/dl) in the euglycemic,
and30.554mg/dl(180mg/dl)inthe
hyperglycemic ranges. Median (inter-
quartile range) of absolute relative differ-
ence to YSI measurement was 22.0 
37.9% (70 mg/dl) in the hypoglycemic,
11.8  17.8% (70–180 mg/dl) in the eu-
glycemic, and 12.8  14.6% (180 mg/
dl) in the hyperglycemic ranges. The
hypoglycemic alert used in this study was
set at 80 mg/dl (considered clinically in-
adequate). This low alert detected hypo-
glycemia (80 mg/dl) with 61%
sensitivity, 91% speciﬁcity, and a positive
predictive value of 90%. In comparison
with SMBG, the CGM system performed
slightly better on day 10 in absolute dif-
ference (median 15.5 mg/dl, P  0.03;
Table 1). However, absolute relative dif-
ference was slightly higher on day 10
when compared with SMBG.
The sensor performance was stable
throughout 10 days of use at home when
data were compared with SMBG values.
Morethan90%ofpairedglucosereadings
fell within the clinically relevant Clarke
error grid zones A and B, as reported pre-
viously, with 3- and 7-day use of sensors
(supplemental Fig. 1A and B, available in
an online appendix at http://dx.doi.org/
10.2337/dc08-1745).
There were no sensor insertion site
infections. Over the 10-day duration of
this study, there were seven incidences of
sensor insertion site effects and two in-
stances of mild erythema with sensor ad-
hesives, and one patient reported mild
bruising at the sensor site.
CONCLUSIONS— This is the ﬁrst
report on the use of transcutaneous
CGM that lasts for 10 days. The SEVEN
system, when used for 10 days (cur-
rently approved for 7 days), was safe
(off-label) and well tolerated with no
skin reactions. The mean absolute rela-
tive difference for CGM versus YSI was
12.6, 11.3, and 14.5% on days 2, 7, and
10, respectively, and did not differ over
the study duration (P  0.63). The sen-
sor performance was stable for 10 days
when compared with SMBG values.
Most CGM devices had reported similar
sensitivity levels for detecting hypogly-
cemia, and these need levels to be im-
proved in future CGM devices. The
longer use of a sensor may result in bet-
ter compliance and health outcomes
andwillbecost-effectiveduetoanextra
3-day use of a 7-day sensor. Increased
sensor use has been correlated with bet-
ter A1C reductions in recent clinical tri-
als (10–15). This is the ﬁrst study to
document that longer sensor usage (10
days) is feasible, safe, and practical.
Long-term impact of 10-day use of
SEVEN on A1C and hypoglycemia
needs to be evaluated.
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Table 1—Differences in glucose values (mg/dl) from CGM in reference to YSI and SMBG
No. of paired
data points
Absolute difference
(mg/dl)* Relative difference (%)†
Absolute relative
difference (%)*
Mean  SD Median Mean  SD Median Mean  SD Median
YSI in-clinic days 2, 7,
and 10§
5.0  27.3 1.4
Overall 905 25.2  25.4 17.3 17.9  21.2 12.9
Day  0.1  18.3 1.2
2 271 23.6  21.1 16.5 4.5  20.5 1.7 14.4  11.3 12.6
7 227 21.2  21.0 16.0 8.7  34.3 1.6 15.7  14.0 11.3
10 407 28.4  29.7 18.8 5.0  27.3 1.4 21.6  27.9 14.5
P 0.08 0.02 0.63
SMBG in-clinic days 2,
7, and 10¶
Overall 1,130 0.9  26.3 4.9 17.7  19.5 13.3
Day  24.8  25.3 17.0
2 379 23.0  22.5 16.0 0.2  21.4 1.9 15.6  14.5 12.8
7 317 20.9  25.1 15.5 2.7  21.3 6.4 15.7  14.6 12.5
10 434 20.9  25.1 15.5
P 0.03 0.002 0.002
Data are mean  SD or median unless otherwise indicated. *Calculated as absolute value of (sensor  YSI) where, for each paired point, sensor  time-matched
continuously measured glucose value and YSI  SMBG values. †Calculated as (sensor  YSI)/YSI. ‡Calculated as the absolute value of (sensor  YSI)/YSI.  From
thetimeofsensorinsertion(in24-hincrements).Pvaluescalculatedbythe
2Kruskal-Wallistestfrommedianvalues.§Percentofpointswithin20%ofreference
70.8%;percentofpointswithin30%ofreference87.6%.¶Percentofpointswithin20%ofreference73.4%;percentofpointswithin30%ofreference88.7%.
Garg, Voelmle, and Gottlieb
DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009 437board for DexCom. No other potential con-
ﬂicts of interest relevant to this article were
reported.
Parts of this study were presented in ab-
stract and poster form at the 68th Scientiﬁc
SessionsoftheAmericanDiabetesAssociation,
San Francisco, California, 6–10 June 2008.
TheauthorsthankDawnWhiteforeditorial
assistanceandSamEllisforhelpingtoconduct
this study.
References
1. The Diabetes Control and Complications
Trial Research Group: The effect of inten-
sive treatment of diabetes on the devel-
opment and progression of long-term
complications in insulin-dependent dia-
betesmellitus.NEnglJMed329:977–986,
1993
2. UK Prospective Diabetes Study (UKPDS)
Group: Intensive blood glucose control
with sulphonylureas or insulin compared
with conventional treatment and risk of
complications in patients with type 2 di-
abetes (UKPDS 33). Lancet 352:854–
865,1998
3. The Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interven-
tionsandComplicationsResearchGroup:
Sustained effect of intensive treatment of
type 1 diabetes mellitus on development
and progression of diabetic nephropathy:
the Epidemiology of Diabetes Interven-
tions and Complications (EDIC) study.
JAMA 290:2159–2167, 2003
4. Nathan DM, Cleary PA, Backlund JY, Ge-
nuth SM, Lachin JM, Orchard TJ, Raskin
P, Zinman B, The Diabetes Control and
Complications Trial/Epidemiology of Di-
abetes Interventions and Complications
(DCCT/EDIC) Study Research Group: In-
tensive diabetes treatment and cardiovas-
cular disease in patients with type 1
diabetes. N Engl J Med 353:2643–2653,
2005
5. The Diabetes Control and Complica-
tions Trial Research Group: The rela-
tionship of glycemic exposure (HbA1c)
to the risk of development and progres-
sion of retinopathy in the Diabetes Con-
trol and Complications Trial. Diabetes
44:968–983, 1995
6. Cryer PE, Davis SN, Shamoon H: Hypo-
glycemia in diabetes. Diabetes Care 26:
1902–1912, 2003
7. Chase HP, Roberts MD, Wightman C,
Klingensmith G, Garg SK, Van Wyhe M,
Desai S, Harper W, Lopatin M, Bartkow-
iak M, Tamada J, Eastman RC: Use of the
GlucoWatch biographer in children with
type 1 diabetes. Pediatrics 111:790–794,
2003
8. Wong L, Buckingham B, Kunselman B,
IstocE,LeachJ,PurvisR:Extendeduseof
anewcontinuousglucosemonitoringsys-
tem with wireless data transmission in
childrenwithtype1diabetesmellitus.Di-
abetes Technol Ther 8:139–145, 2006
9. ClarkeWL,CoxD,Gonder-FrederickLA,
Carter W, Pohl SL: Evaluating clinical ac-
curacy of systems for self-monitoring of
bloodglucose.DiabetesCare10:622–628,
1987
10. Deiss D, Bolinder J, Riveline JP, Battelino
T, Bosi E, Tubiana-Ruﬁ N, Kerr D, Phillip
M: Improved glycemic control in poorly
controlled patients with type 1 diabetes
using real-time continuous glucose mon-
itoring. Diabetes Care 29:2730–2732,
2006
11. Garg S, Zisser H, Schwartz S, Bailey T,
Kaplan R, Ellis S, Jovanovic L: Improve-
ment in glycemic excursions with a trans-
cutaneous, real-time continuous glucose
sensor: a randomized controlled trial. Di-
abetes Care 29:44–50, 2006
12. Garg S, Jovanovic L: Relationship of fast-
ing and hourly blood glucose levels to
HbA1c values: safety, accuracy, and im-
provements in glucose proﬁles obtained
using a 7-day continuous glucose sensor.
Diabetes Care 29:2644–2649, 2006
13. Juvenile Diabetes Research Foundation
Continuous Glucose Monitoring Study
Group, Tamborlane WV, Beck RW, Bode
BW, Buckingham B, Chase HP, Clemons
R, Fiallo-Scharer R, Fox LA, Gilliam LK,
Hirsch IB, Huang ES, Kollman C, Kowal-
ski AJ, Laffel L, Lawrence JM, Lee J, Mau-
ras N, O’Grady M, Ruedy KJ, Tansey M,
Tsalikian E, Weinzimer S, Wilson DM,
Wolpert H, Wysocki T, Xing D: Continu-
ous glucose monitoring and intensive
treatment of type 1 diabetes. N Engl J Med
359:1464–1476, 2008
14. Bailey TS, Zisser HC, Garg SK: Reduction
in hemoglobin A1c with real-time contin-
uous glucose monitoring: results from a
12-week study. Diabetes Technol Ther
9:203–210, 2007
15. Garg SK, Kelly WC, Voelmle MK, Ritchie
PJ, Gottlieb PA, McFann KK, Ellis SL:
Continuous home monitoring of glucose:
improved glycemic control with real-life
useofcontinuousglucosesensorsinadult
subjects with type 1 diabetes. Diabetes
Care 30:3023–3025, 2007
Ten-day use of continuous glucose monitors
438 DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009